Potentiating Psilocybin

增强裸盖菇素

• 批准号: 10354547
• 负责人: DAVID E CLIFFEL
• 金额: $ 23.78万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-05 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10354547
• 关键词: Acer; Alder plant; Beta Carbolines; Biochemical; Cessation of life; Chemicals; Chemistry; Chronic; Cities; Clinical Treatment; Development; Disease; Disease model; Dose; Drug Interactions; Fruit; Grain; Grant; Growth; Hallucinogens; Harvest; Heterogeneity; Human; Humidity; Ingestion; Learning; Legal; Link; Liquid substance; Major Depressive Disorder; Maps; Mental Depression; Mental disorders; Migraine; Modeling; Modern Medicine; Monitor; Monoamine Oxidase Inhibitors; Names; Neurons; Paper; Patients; Pharmaceutical Preparations; Physiological; Plants; Psychotherapy; Publishing; Recording of previous events; Reporting; Research; Research Personnel; Resources; Rye cereal; Sampling; Selective Serotonin Reuptake Inhibitor; Serotonergic System; Serotonin; Serotonin Syndrome; Signal Transduction; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stable Isotope Labeling; Structure; Supplementation; Techniques; Technology; Temperature; Testing; Therapeutic Effect; Toxicology; Tryptophan; Variant; Wheat; base; common treatment; comparative; detection method; high risk; inhibitor therapy; instrument; interest; painful neuropathy; plant fungi; psilocin; psychologic; screening; small molecule; treatment-resistant depression; uptake

PROJECT SUMMARY ABSTRACT Plants and fungi have a long history of medicinal use yet, modern medicine has turned away from plant-based medicinals due to heterogeneity that results in inconsistent and unpredictable dosing. In 2018, psilocybin was granted Breakthrough Therapy Designation for the therapy of treatment-resistant depression. Initial results of psychedelic-assisted psychotherapy using the psilocybin molecule to treat major depressive disorder report sustained relief from chronic conditions after just one treatment—a breakthrough treatment indeed. In our understanding, these studies—and many others investigating psilocybin’s effect on a range of conditions—rely on the psilocybin molecule as the active compound, not Psilocybin Sp.. As this treatment gains support, it’s important to consider the differences between the molecule psilocybin and various Psilocybin species. In 2019 Blei et. al. published an unexpected paper revealing that β- carbolines—monoamine oxidase inhibitors (MAOIs)—are also found in five common Psilocybin sp.. Generally, MAOIs are considered to be counter indicated with Selective Serotonin Reuptake Inhibitors (SSRIs)—common treatments for psychiatric disorders, migraine headaches and neuropathic pain. In fact, patients taking SSRIs have developed serotonin syndrome after ingesting mixtures of serotonergic psychedelics and MAOIs—overwhelming the serotonin system and resulting in death. These counter indications are absent in research that relies exclusively on the psilocybin molecule. It is therefore of critical importance that we understand the chemistry of various psilocybin- containing mushrooms so that clinicians, researchers, policymakers, and the public can make informed decisions. To this end, we propose investigating the β-carboline content in 13 different psilocybin-containing species. (Aim 1), the growth conditions that may vary this content (Aim 2), and their effects on the serotonin system (Aim 3). As city and state legislatures are now legalizing and/or decriminalizing Psilocybin sp., these potential drug interactions represent a high-risk to current SSRI patients. With over 100 different species of psilocybin-containing mushrooms spanning at least six genera, there is a lot to learn as legalization proceeds.

项目摘要